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Abstract
Background:  Different publications show an increased incidence of neoplasms in renal transplant
patients. The objective of this study is to determine the incidence of cancer in the recipients of renal
transplants performed in the A Coruña Hospital (Spain) during the period 1981–2007.
Methods/Design: During the study period 1967 kidney transplants were performed, corresponding to
1710 patients. Patients with neoplasms prior to the transplant will be excluded (n = 38). A follow-up study
was carried out in order to estimate cancer incidence after transplantation.
For each patient, information included donor and recipient characteristics, patients and graft survival and
cancer incidence after transplantation. Incident cancer is considered as new cases of cancer after the
transplant with anatomopathological confirmation. Their location will be classified according to the ICD-9.
The analysis will be calculated using the indirect standardisation method. Age-adjusted cancer incidence
rates in the Spanish general population will be obtained from the Carlos III Health Institute, the National
Epidemiology Centre of the Ministry of Science and Technology. Crude first, second and third-year post-
transplantation cancer incidence rates will be calculated for male and female recipients. The number of
cases of cancer at each site will be calculated from data in the clinical records. The expected number of
cancers will be calculated from data supplied by the Carlos III Health Institute. For each tumour location
we will estimate the standardized incidence ratios (SIRs), using sex-specific cancer incidence rates, by
dividing the incidence rate for the transplant patients by the rate of the general population. The 95%
confidence intervals of the SIRs and their associated p-values will be calculated by assuming that the
observed cancers follow a Poisson distribution. Stratified analysis will be performed to examine the
variation in the SIRs with sex and length of follow-up.
Competing risk survival analysis methods will be applied to estimate the cumulative incidence of cancer
and to identify variables associated to its occurrence.
Discussion: Information about cancer incidence in kidney transplant patients could be useful to adapt the
guidelines on post-kidney transplant follow-up on tumour screening, and evaluate the impact of
intervention measures for the prevention of cancer in these patients.
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Background
Cardiovascular illnesses and neoplasms are the two main
causes of death with normal function of the graft in the
long-term follow-up of patients who have received kidney
transplants [1,2]. The Australian-New Zealand register
even suggests that the second factor could be growing at a
faster rate than the first [3]. The presence of neoplasms is
a major threat and cause of morbidity in kidney transplant
patients.
According to data published in other countries, the accu-
mulated incidence of neoplasms can reach 20% 10 years
from the transplant [4] and nearly 30% after 20 years
[5,6]. The rate of expected cancers compared to those
which are observed varies in the different registers. On
average, it is estimated that the incidence of cancer in
patients who have received kidney transplants is 3 times
higher than that for the general population. By localiza-
tions, this ratio can reach an incidence rate of between 8
and 14 times more for kidney cancer in transplant
patients, and an incidence of between 65 and 92 times
more of non-melanoma skin tumours [4,5,7-11]. In the
largest study on the incidence rates of malignancies
among first-time recipients of deceased or living donor
kidney transplantation (n = 35765) the rates for most
malignancies are higher after kidney transplantation com-
pared with the general population [7]. Similar results were
observed in studies from five national tumour registries in
Denmark [11], Finland [12], Sweden [13], Australia [14],
and Canada [15] with a total sample size of 31,977 trans-
plant recipients.
Several factors may influence in the pathogenesis of
tumours after transplantation: chronic uraemic status,
cumulative exposure to immunosupression, and certain
drugs which can be carcinogenic through independent
mechanisms or as a result of immunosupression and viral
infections. Some authors suggest that immune deficiency,
rather than other risk factors for cancer, is responsible for
the increased risk [16].
The use of immunosuppressive agents to prevent allograft
rejection increases the long-term risk of malignancy com-
pared with that of the general population. In this case,
cyclosporine and tacrolimus have been identified as onco-
genes in themselves, through a mechanism which
involves TGF-β [17,18]. However, the data published to
date do not make it possible to obtain conclusive results.
Despite the increased risk, little is known about the over-
all cancer prognosis, screening, treatment strategies, and
effectiveness in this population [19], and strategies to
understand and minimize the risk of developing malig-
nancy in the transplant population are needed [20]. Some
authors describe this uncertainty as an "unmet medical
need" [21].
Most of the information regarding the incidence of post-
transplant tumours comes from multi-centre registries, in
which the data gathering process may be incomplete, and
which may lead to an underestimation of the true inci-
dence of malignant cancers. Also, it is difficult to estimate
the incidence of the majority of tumours and their associ-
ated factors based on studies carried out in a single hospi-
tal, which normally involve a small number of patients.
Knowledge of the true incidence of cancer in patients who
have undergone kidney transplants in our surroundings
could alert us to the need to establish tumour screening
policies which permit early intervention, as has been
established in the European Guidelines for kidney trans-
plant follow-up [22-24]. Promoting healthy lifestyles and
carrying out regular tests on patients that permit the early
diagnosis of tumour complications could contribute
towards palliating the morbidity-mortality of these
patients.
The aim of this study is to establish the incidence of cancer
in recipients of renal transplants performed in a hospital
in A Coruña (Spain) during the period 1981–2007 com-
pared to that experienced by the general population. This
centre, the University Hospital Complex of A Coruña, has
the same level of activity as the national average, at
around 50 interventions per million population per year.
Methods/Design
An observational prospective follow-up study with a retro-
spective component, carried out in the health district of A
Coruña (northwest Spain) during the period 1981–2007.
During that period 1967 kidney transplants were per-
formed in the University Hospital Complex of A Coruña,
which corresponded to 1710 patients. Patients with pre-
transplant neoplasms will be excluded from the analysis
(n = 38). A follow-up study was designed in order to esti-
mate cancer incidence after kidney transplantation. This
sample size would make it possible to detect relative risks
of ≥1.2 estimating an exposed proportion of 35% and a
proportion of censured observations of 40%, with a secu-
rity of 95% and a statistical power of 80%.
Patients who had received transplants were identified
through the hospital's transplant registry. For each
patient, information includes donor and recipient charac-
teristics, patient and graft survival and cancer incidence
after transplantation. The variables are summarized in the
Appendix.BMC Cancer 2009, 9:294 http://www.biomedcentral.com/1471-2407/9/294
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The study was approved by the region's Ethics Committee
for Clinical Research (CEIC Galicia) and written informed
consent was obtained from all of patients who have par-
ticipated in the study.
Follow-up period
The period of follow-up for each patient starts on the day
of transplantation and continues until death or last
reported contact. Following the methodology used in sim-
ilar studies, patients will not be removed from the analysis
at the time of graft failure for several reasons [14,25]: (i)
cancer risk is likely to persist despite graft failure or, oth-
erwise, the risk of malignancy is unlikely to return to pre-
transplant levels following graft failure, (ii) previous stud-
ies have established that dialysis is also associated with
increased cancer risk in comparison with the general pop-
ulation, and (iii) we think it is important to inform clini-
cians and patients about cancer risks following
transplantation.
Determining the incidence of cancer after transplantation
Incident cancer is considered as new cases of cancer which
occur after the transplant and which have anatomopatho-
logical confirmation. Their localization will be classified
according to the International Classification of Diseases-9
(ICD-9). Observed cancers are those reported at any time
after the date of first transplantation, and include those
that occurred after a subsequent transplant, following a
"once transplanted always transplanted" rule [5].
Comparing cancer after transplantation with cancer in the 
Spanish population
The analysis will be calculated using the indirect standard-
isation method. Estimates of age-adjusted cancer inci-
dence rates in the general population of Spain will be
obtained from the Carlos III Health Institute, the National
Epidemiology Centre of Spain's Ministry of Science and
Technology.
Crude first, second and third-year post-transplantation
cancer incidence rates will be calculated for male and
female recipients. The number of observed cases of cancer
at each site will be calculated from data in the clinical
records.
The expected number of cancers will be calculated from
data supplied by the Carlos III Health Institute. For each
tumour location we will estimate the standardized inci-
dence ratios (SIRs) of cancer, using sex-specific cancer
incidence rates, by dividing the incidence rate for the
transplant patients by the rate of the general population.
The 95% confidence intervals of the SIRs and their associ-
ated p-values will be calculated by assuming that the
observed cancers follow a Poisson distribution. Stratified
analysis will be performed to examine the variation in the
SIRs with sex and length of follow-up.
Estimating the incidence of cancer over time
Competing risk survival analysis methods will be applied
to estimate the cumulative incidence of developing cancer
over time from kidney transplantation.
This method allows for the fact that a patient may experi-
ence an event which is different from the event of interest.
These events are known as competing risk events, and may
preclude the onset of the event of interest, or may modify
the probability of the onset of the event of interest. In par-
ticular, a transplanted patient may die or lose the graft
without developing any kind of cancer. In a Kaplan-Meier
estimation approach, these persons would be treated as
censored and would be eliminated from the risk set. This
could lead to misleading results, as it is based on the
assumption that censoring is "non-informative", meaning
that a censored patient has the same risk of developing
cancer as those who have complete follow-up. This is not
the case in patients who die before without developing
cancer, as they are no longer at risk.
Occurrence of cancer will be the event of interest. Any
other event, such as death of graft failure, will be consid-
ered competing events. Estimates of cumulative incidence
functions will be calculated based on the two-step process
developed by Kalbfleisch and Prentice [26]. In the first
step, we will calculate the Kaplan-Meier estimate of the
overall survival from any event. In the second step, the
conditional probabilities of developing cancer will be cal-
culated. The cumulative incidences will be estimated
using these probabilities. Differences between the cumu-
lative incidence functions according to patient character-
istics will be tested for statistical significance using the
method developed by Gray [27]. The cumulative inci-
dence function regression model of Fine and Gray [28]
will be used for multiple regression analyses.
Statistical analysis will be performed by using the R statis-
tical package (version 2.9. 2009; The R Foundation for
Statistical Computing) [29] and EPIDAT statistical soft-
ware (version 3.1, 2006; Dirección Xeral de Saude
Pública, Organización Panamericana de la Salud) [30]. P-
values of < 0.05 are considered statistically significant.
Discussion
This study will provide us with information on the risk of
developing cancer in kidney transplant patients, and will
allow us to increase the level of vigilance over the inci-
dence of cancers in this population, especially for
tumours for which there are no population-based screen-
ing programmes.BMC Cancer 2009, 9:294 http://www.biomedcentral.com/1471-2407/9/294
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The interval between transplantation and diagnosis of
cancer is time dependent, so the follow-up period will let
us know if the incidence is modified with length of fol-
low-up. Even though there is variability dependent on the
type of tumour and age of the patient, it has been
described that the average latency period is approximately
three to five years after transplantation [31-34].
Furthermore, this study will provide us with information
on the variables associated with the presence of cancer in
kidney transplant patients, and allow us to adapt the
European Guidelines on post-kidney transplant follow-up
on tumour screening to our environment[35].
Although the information will be taken from hospital
records, which could lead to a bias in the information, the
characteristics of these patients mean that they are sub-
jected to more exhaustive follow-up than normal, not
only during the immediate post-transplant period, but
also during the years after the transplant. During the first
year after the transplant they are seen at least every 3
months, every 6 months from one year after the trans-
plant, and after 10 years are seen at least once a year. This
fact would minimize any possible bias in the information.
The use of data from a single centre could also hinder the
calculation of the incidence of less frequent tumours. It is
also true that as indicated in a number of publications,
neither is the incidence of cancer in populational regis-
tries of transplant patients free from errors, as the report-
ing of cancer to the registry is often incomplete, and this
could lead to an underestimation of the incidence [7].
Spain has the highest cadaver donor rate in the world, and
is the leading country at international level in terms of
performance in renal transplantations per million popu-
lation (pmp) [36]. The hospital in which we are going to
carry out this study, the University Hospital Complex of A
Coruña, is located in the Autonomous Region of Galicia,
which has the same level of activity as the national aver-
age, at around 50 interventions per million population
per year [37].
Little is known about the advantages and disadvantages of
cancer screening, treatment effectiveness, and overall can-
cer prognosis in renal transplant recipients [38].
This study will allow us to know the scale of the problem
in kidney transplant patients, and to evaluate the impact
of intervention measures for the prevention of cancer in
these patients in the future.
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Appendix
Study measurements
PATIENT
Date of transplantation
Age at transplantation
Gender
Body mass index
Primary renal disease: diabetic nephropathy, glomeru-
lonephritis, hypertensive and arteriopathic conditions
and others.
Prior time spent on dialysis, and dialysis modality
Pre-transplant cancer
Smoking status at transplant and during follow-up
Cancer diagnosis:
Post-transplant cancer
Date of the diagnosis of cancer
Cancer location (ICD-9)
Histopathology
Follow-up:
Type of immunosuppressive treatment:
Cyclosporine
Azathioprine
Mycophenolate Mofetil (MMF)
Sirolimus, Everolimus
Tacrolimus
PrednisoneBMC Cancer 2009, 9:294 http://www.biomedcentral.com/1471-2407/9/294
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Induction therapy: OKT3, baxiliximab, dacli-
zumab, thymoglobulin and ATG
Dose of immunosuppressive medication
Treatment changes during follow-up
Graft failure
Kidney rejection episodes
New kidney transplants
Death, cause of death
Date of last contact
DONOR
Age
Gender
Donor kidney source: cadaveric, living unrelated, liv-
ing related
HLA mismatches
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